Biotech
-
Why Maravai LifeSciences Could Be a Perfect Acquisition Target for Repligen
Maravai LifeSciences has recently caught the attention of Repligen as a potential acquisition target, marking it as a significant player…
Read More » -
SmallCaps Daily Sits Down with Milton Werner, President and CEO of Inhibikase Therapeutics
CEO and President, Milton Werner shares Inhibikase's vision, achievements, and future endeavors in neurological diseases while highlighting the significant progress…
Read More » -
Travere’s Recent Breakthrough Drug Sends Its Stock Soaring: What Investors Need To Know Now!
Travere Therapeutics' completion of a successful pre-NDA meeting with the U.S. FDA for Filspari in IgA nephropathy has sent its…
Read More » -
OKYO Pharma: An Emerging Biopharma With Game Changing Treatments In Ophthalmology
OKYO Pharma's main drug has already surpassed Phase 1 and reached Phase 2. OK-101 is catering to niches within the…
Read More » -
Pond Technologies: Value Through Vertical Integration Creates Catalysts For Investors
With increasing industrial activity resulting in a significant impact on the environment, CO2 abatement has become an urgent need for…
Read More » -
Quipt Home Medical Corp: The Deeply Undervalued Home Medical Company Helping Create a Safer Post Pandemic World
Quipt Home Medical is a leader in providing clinical respiratory equipment including BiPAP and CPAP machines, oxygen concentrators, sleep apnea…
Read More » -
Massive Breakthrough for Young Biotech Company Longeveron, Shown in Promising Phase 2b Trial Results
Young and dynamic biotech company Longeveron (Nasdaq:LGVN) announced topline results of their Phase 2b study of Lomecel-B for aging frailty,…
Read More » -
Longeveron (LGVN): The Highest Growth Potential Company Presenting at the AAIC
It is estimated that 44 million people globally are suffering from Alzheimer’s disease with 5.5 million of them in the…
Read More » -
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application
Shelton, Connecticut — March 2, 2021 — NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) a leader in the development of highly…
Read More » -
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 – Has Sufficient Cash, Coronavirus Drug Candidate Safe in GLP Safety Toxicology Moving Towards IND
SHELTON, CONNECTICUT – February 16, 2021 — NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) a global leader in the development of…
Read More »